Translational Team Science

 

Translational Team Science Program

Purpose: To foster collaborations between basic and clinical scientists by supporting new research teams to conduct initial studies and establish funded translational research programs. The expected outcome from the selected team is the submission of one competitive NIH R01 proposal (or equivalent), in two years and two publications. 

Target Faculty: Active faculty with a primary appointment in the College of Medicine, and with a strong history of funding, publications, and a record of MUSC service.

Application Timeline: Team Building Phase announced in January each year:

Step 1: Senior Research Dean issues call for developing new collaborations. (Dean’s newsletter and direct email with links for survey, etc.)

Step 2: Interested individuals are invited to complete a REDCap survey to share their interests with potential collaborators (Survey closes in January; responses to be shared on this page in February)

Step 3: Applicants select/identify a basic scientist or clinical scientist for team collaboration.

Team Organization and LOI: Letters of Intent announced in February and due in March. 

LOI to include: The team members’ names, credentials, ranks, and departments/divisions; the general area of research that the grant will be centered around; the significance and innovation of the expected grant proposal; existing preliminary data and new data that will be developed from the collaboration to support new R01 application, or equivalent, and team publications; and a statement that the chair(s) support(s) the application and is/are copied on the letter. (Two page limit)

Applications by Invitation Only.  Invitation for applications in April; application for selected teams due in May; reviewed and awarded in June. Teams must consist of at least one basic science and one clinical science faculty member. R21 grant format.  Application Review in June by the Senior Associate Dean and a designated committee will determine if funding and research goals are on target and make recommendations to the Dean. Final funding decisions will be made by the Dean of the College of Medicine with target date of July.

Outcome: Submission of a competitive NIH R01 proposal, or equivalent, from PIs, in two years and two publications.

Award Funding: $100K/year for 2 years. One award per year

Scientific Focus: Basic, translational, or clinical research. Priority given to research in MUSC and MUSC Health strategic areas.

Application Review & Oversight: A panel of funded senior MUSC investigators and one external reviewer, selected by the Senior Associate Dean, will review full applications. The review panel will make recommendations, to the Dean and the Senior Associate Dean for Research, regarding the significance and innovation of the research programs, and the ability of the team to compete for extramural funds. The Dean will make the final funding decision. Decisions about continuation of funding will occur every 6 months based on meeting or exceeding specific milestones. The initial review team, the Senior Associate Dean, and Department Chair(s) will participate in these reviews.

Factors Considered in Application Review: Publication history; grant history; team strength; program innovation, significance, and translational impact; and alignment with MUSC Health and College of Medicine strategic goals.

Program Expectations and Milestones:

  • Progress Report & Review at 6 Months of Funding (January). First paper submitted or final draft. Progress on grant application (aims, preliminary data, etc.)
  • Progress Report & Review at 12 Months of Funding (July). Second paper in final draft form or submitted. Progress on grant application (aims, preliminary data, etc.)
  • Progress Report & Review at 18 Months of Funding (January). Grant submitted  (external grant review if warranted). Review of publications. Future grant submissions (aims, preliminary data, etc.)
  • Progress Report at 24 Months: Written report (July)

Please note announcement and due dates subject to change:  For additional information contact Mary McConnell.